

CERTARA[®]

CODEX Clinical Outcomes Databases

Atopic Dermatitis (ADERM)



Curated clinical trial data for earlier, confident decisions

Certara's Clinical Trial Outcomes Database (CODEX) is an expertly curated database of clinical trial data for marketed and pipeline drugs, covering 8 therapeutic areas and 70+ indications. It includes structured and unstructured data that can be downloaded and integrated with internal datasets to support modeling and simulation, enabling earlier, more confident drug development decisions.

With CODEX, you can:



Identify the right trial populations

analyze clinical data to identify target populations for new studies.



Improve study design

refine sample size calculations to reduce costs and increase success rates.



Strengthen regulatory strategy

review integrated summaries of safety and efficacy (ISS/ISE) for similar products to inform regulatory approval strategies.



Demonstrate commercial viability

run economic models to generate additional data points that can be used to demonstrate value to payers and in competitive pricing assessments.

Model-based meta-analysis (MBMA)

MBMA leverages CODEX databases and pharmacology models to increase development productivity, quantitatively inform portfolio decisions, and improve clinical trial success. It optimizes trial design, including timing, endpoints, and dosing, as well as competitive landscape assessment. MBMA also bridges across studies, allowing comparison of treatments and patient populations that may not have been evaluated within the same trial.



196 studies

Key Efficacy & Biomarker Endpoints (EASI, IGA, pruritus NRS, BSA, IgE, TARC, ALT and AST)



49,000 patients

All systemic or novel pharmacological treatments with primary focus on topical treatments



104,000

Longitudinal Data Points – Format available in Excel and CODEX (Clinical Outcomes Database Explorer)

A comprehensive repository of ADERM clinical outcomes

The CODEX Atopic Dermatitis (ADERM) Database supports decision-making across the drug development continuum, informing both clinical trial performance and competitive positioning. It is curated to capture clinical efficacy and biomarker data from all randomized, placebo- and active-controlled trials in atopic dermatitis. Included studies also feature washout and add-on designs.

Randomized.drug (top 9)	Class	Studies
dupilumab	anti-IL-4/13	23
baricitinib	JAK inhibitor	10
tralokinumab	anti-IL-13	10
abrocitinib	JAK inhibitor	11
lebrikizumab	anti-IL-13	11
crisaborole	PDE4 inhibitor	8
tapinarof	NSAID	8
upadacitinib	JAK inhibitor	8
tacrolimus	immunosuppressant	8

Table 1. The top 9 drugs in the CODEX ADERM database




Figure 1. Snapshot of select treatments; EASI time course




Figure 2. EASI time course for trials with dupilumab

Discover how CODEX can empower more confident decisions.

To learn more or request a demo, visit certara.com/codex

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Visit certara.com | Copyright ©2026 Certara. All rights reserved.

CERTARA